ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 517 • 2017 ACR/ARHP Annual Meeting

    Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis

    Jenny Wan1, Michele Spence2, Fang Niu2, Rita Hui3, Stephen Cheng1, Logan Saito4 and Antony Lin5, 1Kaiser Permanente Drug Information Services - California Regions, Downey, CA, 2Kaiser Permanente Pharmacy Outcomes Research Group, Downey, CA, 3Kaiser Permanente Pharmacy Outcomes Research Group, Oakland, CA, 4Kaiser Permanente Southern California Clinical Pharmacy Services, Downey, CA, 5Rheumatology, Kaiser Permanente Fontana Medical Center, Fontana, CA

    Background/Purpose: Systemic methotrexate (MTX) is the first-line disease-modifying antirheumatic drug (DMARD) for treating early and established rheumatoid arthritis (RA). When compared to oral MTX, subcutaneous…
  • Abstract Number: 518 • 2017 ACR/ARHP Annual Meeting

    The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients

    Antony Lin1, Qiaowu Li2, Jiaxiao Shi2, Serena Lin3, Danielle Wang4, Jenny Wan5, Kevin Lee3, Hung-Fu Tseng2 and TC Cheetham6, 1Southern California Permanente Medical Group, Pasadena, CA, 2Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, 3Stanford University, Stanford, CA, 4UCI Medical Center, Irvine, CA, 5Kaiser Permanente Drug Information Services - California Regions, Downey, CA, 6Western University of Health Sciences, Pomona, CA

    Background/Purpose:   To investigate the efficacy and safety of zoster vaccines administered in rheumatoid arthritis(RA) patients taking methotrexate(MTX). Methods:   By reviewing data through the…
  • Abstract Number: 519 • 2017 ACR/ARHP Annual Meeting

    Filgotinib, a Selective Janus Kinase 1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

    Kacey Anderson1, Hao Zheng2, Chohee Yun3, Ellen Kwan4, Ann Qin1, Florence Namour5, Brian P. Kearney1 and Yan Xin1, 1Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA, 2Gilead Sciences, Inc., Foster City, CA, 3Clinical Research, Gilead Sciences, Inc, Foster City, CA, 4Clinical Operations, Gilead Sciences, Inc, Foster City, CA, 5Galapagos NV, Romainville, France

    Background/Purpose: Filgotinib is a potent and selective Janus kinase 1 (JAK1) inhibitor being developed to treat inflammatory diseases. Safety pharmacology studies and Phase 1 studies…
  • Abstract Number: 520 • 2017 ACR/ARHP Annual Meeting

    Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach

    Norman Gaylis1, Joanne Sagliani1 and Steven Needell2, 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, 2Boca Radiology, Boca Raton, FL

    Background/Purpose: Tofacitinib has been shown to reduce the clinical signs and symptoms of some RA patients at an approved dose of 5 mg bid. Studies…
  • Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting

    Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis

    Mauro Galeazzi1, Gian Domenico Sebastiani2, Jürgen Wollenhaupt3, Jean Dudler4, Christof Specker5, Reinhard Voll6, Pascal Zufferey7, Piercarlo Sarzi Puttini8, Ombretta Viapiana9 and Franziska Bootz10, 1Rheumatology, University Hospital of Siena, Siena, Italy, 2Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, 3Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 4Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, 5Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, 6Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, 7Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 8Rheumatology, Luigi Sacco Hospital, Milan, Italy, 9University Hospital Verona, Verona, Italy, 10Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland

    Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
  • Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years

    Jürgen Wollenhaupt1, Joel Silverfield2, Eun Bong Lee3, Ketti Terry4, Kenneth Kwok5, Sander Strengholt6, Ryan DeMasi7 and Lisy Wang4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Capelle aan den IJssel, Netherlands, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
  • Abstract Number: 523 • 2017 ACR/ARHP Annual Meeting

    Prevalence of Occult Hepatitis B Carrier Status and Its Associated Risk Factors in Patients with Rheumatic Diseases Undergoing Biological Therapies

    Chi Chiu Mok1, Ling Yin Ho2, Kar Li Chan1, Sau Mei Tse1 and Chi Hung To3, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, 3Medicine, Pok Oi Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the prevalence of occult hepatitis B carrier status and its associated factors in patients with rheumatic diseases undergoing biological therapies Methods: Consecutive…
  • Abstract Number: 524 • 2017 ACR/ARHP Annual Meeting

    Predictors of Mortality in RA Patients before Biologic Therapy

    Debora Cordeiro Rosario1, Camila Nobre Bulhoes1, Rodrigo Peres Toledo1, Karina Bonfiglioli2, Ana C.M. Ribeiro3, Julio C. B. Moraes2, Carla G.S. Saad2, Clovis A Silva4, Eloisa Bonfa5 and Nadia E Aikawa2, 1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Several studies have evaluated mortality risk factors in rheumatoid arthritis (RA) but that are no data regarding baseline predictors of mortality in patients under…
  • Abstract Number: 525 • 2017 ACR/ARHP Annual Meeting

    Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center

    Richard Meehan1, Isabelle Amigues2, David Muram3, Eric Hoffman4, Jim Crooks5, Tho Truong6 and Pearlanne Zelarney7, 1MEDICINE, National Jewish Health, Denver, CO, 2Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 3Eli Lilly and Company, Indianapolis, IN, 4Medicine/Rheumatology, National Jewish Health, Denver, CO, 5Biostatistics, National Jewish Health, Denver, CO, 6Rheumatology, National Jewish Health, Denver, CO, 7Bioinformatics, National Jewish Health, Denver, CO

    Background/Purpose: The goal of therapy of rheumatoid arthritis (RA) is to achieve a state of low disease activity (LDA) or remission and reduce joint damage…
  • Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting

    Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition

    Eun Ha Kang1, Yinzhu Jin2, Sara Dejene3, Gregory Brill3, Rishi J. Desai2, Jeffrey A. Sparks4 and Seoyoung C. Kim5, 1Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
  • Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study

    Seoyoung C. Kim1, Daniel H. Solomon1, James R. Rogers2, Sara Gale3, Micki Klearman3, Khaled Sarsour3 and Sebastian Schneeweiss2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Genentech, South San Francisco, CA

    Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
  • Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting

    Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents

    Christopher Banse1, Nicolas Chrin2, Pascal Rottenberg3, Sophie Pouplin4, thierry Lequerre5 and Olivier Vittecoq3, 1Rheumatology, Rouen University Hospital, Rouen, France, 2Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, 3INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 4Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 5Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France

    Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
  • Abstract Number: 529 • 2017 ACR/ARHP Annual Meeting

    Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience

    Edurne Guerrero Basterretxea1, Maria Luz Garcia Vivar1, Itziar Calvo Zorrilla1, Oihane Ibarguengoitia2, Eva Galíndez Agirregoikoa2, Juan Maria Blanco Madrigal3, Esther Ruíz Lucea1, Ignacio Torre Salaberri1, Olaia Begoña Fernandez Berrizbeitia2, Clara Eugenia Perez1, Ana Rosa Intxaurbe Pellejero2, Natalia Rivera-García4 and Iñigo Gorostiza Hormaetxe5, 1RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 2RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, BILBAO, Spain, 3Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 4RESEARCH, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 5RESEARCH, Research Department. Basurto University Hospital, BILBAO, Spain

    Background/Purpose: Use of biological therapy (BT) has dramatically improved Rheumatoid Arthritis (RA) management and outcomes for the last decade. Classic extraarticular manifestations are now uncommon,…
  • Abstract Number: 530 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials

    Sumit Kunwar1, Christopher E. Collins2 and Florina Constantinescu2, 1Rheumatology, MedStar Washington Hospital Center, washington, DC, 2Rheumatology, MedStar Washington Hospital Center, Washington, DC

    Background/Purpose:  Janus kinases (JAKs) play an important role in intracellular signaling for multiple cytokines in the pathogenesis of RA. Baricitinib is an oral, selective JAK…
  • Abstract Number: 531 • 2017 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials

    Natalia Zamora1,2,3, Maria A. Lopez-Olivo1, Jean Tayar1, Robin Christensen2 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, 3Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina

    Background/Purpose: To explore the comparative effectiveness of tofacitinib or baricitinib in patients with rheumatoid arthritis (RA) following a systematic review of randomized trials, by performing…
  • « Previous Page
  • 1
  • …
  • 1238
  • 1239
  • 1240
  • 1241
  • 1242
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology